By I. Edwards HealthDay ReporterFRIDAY, June 6, 2025 (HealthDay News) — Attorneys general from four states are asking the U.S. Food and Drug Administration (FDA) to lift restrictions on mifepristone, a pill used in medication abortions.The request came Thursday from top officials in California, Massachusetts, New Jersey and New York.They …
Read More »Caregiver Concern Can Be Key to Identifying Critical Illness in Hospitalized Children
Among pediatric patients, caregiver concern more strongly associated with ICU admission than any abnormal vital sign
Read More »Dapagliflozin Beneficial for Improving MASH Without Worsening Fibrosis
Dapagliflozin results in more patients with improved or resolved MASH without worsening of fibrosis, improved fibrosis without worsening of MASH
Read More »Less ‘Experienced Weight Stigma’ After Bariatric Surgery Aids Mental Health
Changes from pre- to post-metabolic bariatric surgery weight stigma predict mental health, dysregulated eating, body mass index
Read More »P2Y12 Inhibitor Monotherapy Beneficial for Patients Who Undergo PCI
Risk for major adverse cardiac and cerebrovascular events lower compared with aspirin monotherapy for patients who undergo PCI and discontinue DAPT
Read More »Early, Preemptive Kidney Transplant No Aid to Mortality
Rates of preemptive kidney transplants remained at ~18 percent of total kidney transplants from 2000 to 2020
Read More »Obesity Linked to Subsequent Neoplasms in Childhood Cancer Survivors
Higher physical activity was associated with reduced subsequent neoplasm risk overall and for specific cancers
Read More »Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast Cancer
No reduction seen in risk with adjuvant regional nodal irradiation among patients with node-positive breast cancer who reached ypN0 status after neoadjuvant chemo
Read More »Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease
Risk for breast cancer-related death and odds of mastectomy were higher for symptom-detected cancer
Read More »ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
Better event-free survival outcomes seen for durvalumab plus FLOT versus FLOT alone in phase 3 randomized trial
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.